AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Paradigm Biopharmaceuticals Ltd

0.004

0.000

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:0.004

Open:0.004

Low:0.004

Close:0.004

52wk High:0.004

52wk Low:0.004

Shares:- -

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Paradigm Biopharmaceuticals Ltd

Exchange:

ASX

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.paradigmbiopharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PARO.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PARO.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PARO.AU\",,,,,undefined,":{"symbol":"PARO.AU","market":"AU","secType":"STK","nameCN":"Paradigm Biopharmaceuticals Ltd","latestPrice":0.004,"timestamp":1771563600000,"preClose":0.004,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Paradigm Biopharmaceuticals Ltd","floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:00:00 AEDT","open":0.004,"high":0.004,"low":0.004,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771801200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.004,"openAndCloseTimeList":[[1771542000000,1771563600000]],"volumeRatio":0,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PARO.AU\",,,,,undefined,":{"symbol":"PARO.AU","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0.004,"amplitude":0,"preClose":0.004,"low":0.004,"week52Low":0.004,"pbRate":"--","week52High":0.004,"institutionHeld":0,"latestPrice":0.004,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.004,"prevYearClose":0.004,"prevWeekClose":0.004,"prevMonthClose":0.004,"prevQuarterClose":0.004,"fiveDayClose":0.004,"twentyDayClose":0.004,"sixtyDayClose":0.004},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PARO.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PARO.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.paradigmbiopharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0113},{"period":"3month","weight":0.0666},{"period":"6month","weight":0.055},{"period":"1year","weight":0.2181},{"period":"ytd","weight":0.0215}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.","exchange":"ASX","name":"Paradigm Biopharmaceuticals Ltd","nameEN":"Paradigm Biopharmaceuticals Ltd"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PARO.AU\",market:\"AU\",,,undefined,":null}}